Enrolling Clinical Trials

Program in Immunology

Enrolling Clinical Trials

Program in Immunology team members are involved in a number of immunotherapy clinical trials enrolling patients with a range of different cancers, including trials of adoptive T cell therapy, studies using specific T cell subsets in stem cell transplantation and trials of T cell-activating vaccines and drug treatments, as listed below.  

We have already used innovative immunotherapies to boost survival rates for patients with leukemia and other blood cancers for whom no other treatment had worked. And, we are developing immune-boosting treatments for patients with other serious non-malignant and malignant diseases, including some of the most challenging solid tumors, like lung, pancreatic and ovarian cancers. Our goal is to create safe and effective immunotherapies for patients around the world.

Open Clinical Trials

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Phase I/II study in WT1-expressing non-small cell lung cancer and mesothelioma, comparing cellular adoptive immunotherapy with polyclonal autologous central memory to naïve CD8+ T cells that have been transduced to express a WT1-specific T cell receptor

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion with Cyclophosphamide and Fludarabine For Patients With Metastatic Melanoma

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed  Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Phase I/II Study of Adoptive Immunotherapy with Virus Specific CD8+ T Cells that have been Transduced to Express a WT1-Specific T Cell Receptor for Patients with High Risk or Relapsed AML, MDS, or CML

Laboratory Treated (CD19 chimeric antigen receptor) T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor

Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD
A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors for Prevention of GVHD

Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children
A Phase II Study of Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children

NY-ESO-1-specific T Cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy
A pilot trial of NY-ESO-1-specific T cells in patients with metastatic NY-ESO-1-expressing sarcomas receiving palliative radiation

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Metastatic Sarcoma
A Phase I Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) with Radiation in Patients with Metastatic Sarcoma